References to Primary Literature
- PRICE FW, WELLEMEYER M: Long-term results of Moheno implants. Ophthalmic Surg. (1995) 26:130.
- KRUPIN T, PODOS SM, BECKER B, NEWKIRK JB: Valveimplants in filtering surgery. Am. J. Ophthalmol. (1976) 81:232.
- KRUPIN T, RITCH R, CAMRAS CB et at: A long Krupin-Denver valve implant attached to a 180° scleral explant for glaucoma surgery. Ophthalmology (1988) 95:1174.
- THE KRUPIN EYE VALVE FILTERING SURGERY STUDYGROUP: Krupin eye valve with disk for filtration sur-gery. Ophthalmology (1994) 101:651.
- COLEMAN AL, HILL R, WILSON MR et al: Initial clinical experience with the Ahmed glaucoma valve implant. Am.J. Ophtbalmol. (1995) 120:23.
- PRATA JA, MERMOUD A, LABREE L, MICKLER DS: In vitro and in vivo flow characteristics of glaucoma drainage Implants. Ophthalmology (1995) 102:894.
- HODKIN MJ, GOLDBLATT WS, BURGOYNE CF, BALL SF,INSLER MS: Early clinical experience with the Baerveldt Implant in complicated glaucoma. Am. J. Ophthalmol. (1995) 120:32.
- STRAHLMAN E, TIPPING R, VOGEL M AND THE INTERNA-TIONAL DORZOLAMIDE STUDY GROUP: A double-masked, randomized 1-year study comparing dorzo-lamkle (Trusopt), timolol, and betaxoloL Arch. ophthal-mot (1995) 113:1009.
- WOODWARD DF, CHAN MF: Recent developments inglaucoma therapy. Curr. Opin. Ther. Patents (1992) 2:287.
- CHIEN D-S, BUNDGAARD H, LEE VHL: Influence of cor-neal epithelial integrity on the penetration of timolol prodrugs.j Ocuhar Pharmacol. (1988) 2:137.
- HARTMAN GD, HALCZENKO W, SMITH RE et al.: 4-substi-tuted thiophene - and furan-2-sulfonamides as topical carbonic anhydrase inhibitors. J. Med. Chem. (1992) 35:3822.
- HUNT CA, MALLORGA PJ, MICHELSON SR et al.: 3- substi-tuted thieno [2,3-b) [1,4] thiazine-6-sulfonamkles. A novel class of topically active carbonic anhydrase in-hibitors. J. Med. Chem. (1994) 37:240.
- SCHOLZ TH, SONDEY JM, RANDALL WC et al.: Suffonyi-methanesulfonatnide inhibitors of carbonic anhy-drase. J. Med. Chem.(1993) 36:2134.
- HARTMAN GD, HALCZENKO W, PRUGH JD etal.: Thieno[2,3-b] furan-2- sulfonamides as topical carbonic anhy-drase inhibitors.' Med. Chem, (1992) 35:3027.
- STEWART WC, RITCH R, SHIN DH et at AND THE APRACLO-NIDINE ADJUNCTIVE THERAPY STUDY GROUP: The effi-cacy of apradonidine as an adjunct to thnolol therapy. Arch. Ophthalmol. (1995) 113P:287.
- BUTLER P, MANNSCHRECK M, LIN S, HWANG I, ALVARADOJ: Clinical experience with long-term use of 1% apraclo-nidine. Arch. Ophthalmol. (1995) 113:293.
- NAGASUBRAMANIAN S, HITCHINGS RA, DEMAILLY P etal:Comparison of apraclonidine and timolol In chronic open-angle glaucoma. Ophthalmology (1993) 100:1318.
- SCHUMAN J AND THE BRIMONIDINE STUDY GROUP: Thelong term safety and efficacy of brimonidine 0.2% in the treatment of glaucoma and ocular hypertension. International Symposium on Experimental and Clinical Ocu-lar Pharmacology and Pharmaceutics (1995) Abstract 29.
- SPADA CS, NIEVES AL, BURKE JA, WOODWARD DF: Com-parative effects of brirnonidine, p-aminoclonidine and clonidine on arteriolar caliber in human retinal tissue. Invest, Ophthalmol. Vis. Sci. (1995) 36:51041.
- ERNSBERGER PR, WESTBROOKS KL, CHRISTEN MO, SCHAFER SG: A second generation of centrally acting antihypertensive agents act on putative Ii-imidazoline receptors./ Cardiovasc. Pharmacol. (1992) 20\(Suppl. 4):51.
- MUNK SA, WIESE A, THOMPSON CD, MACDONALD T: Oxidation potential and allergic response of az agonists. Invest. Ophthalmol. Vis. Sci. (1996) 37:5832.
- SAKURAI M, ARAIE M, OSHIKA T, MORI M, MASUDA K,UENO R, TAKASE M: Effects of topical application of UF-0211, a novel prostaglandin derivative, on aqueous humor dynamics in normal human eyes. Jpn j. Ophthal-mol. (1991) 35:156.
- CAMRAS CB AND THE UNITED STATES LATANOPROST STUDY GROUP: Comparison of latanoprost and timoloi In patients with ocular hypertension and glaucoma_ Ophthalmology (1996) 103:138.
- LILJEBRIS C, SELEN G, RESUL B, STJERNSCHANTZ J, HACK- SELL U: Derivatives of 17-phenyl-I8, 19, 20- trinorpro-stagiandin F2a isopropyl ester: potential anti-glaucoma agents. J. Med. Chem. (1995) 38:289.
- WOODWARD DF, BURKE JA, WILLIAMS LS et al.: Pro-staglandin F2a effects on intraocular pressure nega-tively correlate with FP-receptor stimulation. Invest. Ophthalmol. Vis. Sci. (1989) 30:1838.
- NAKAJIMA M, GOH Y, AZUMA I, HAYAISHI 0: Effects ofprostaglandin D2 and its analogue, BW 245C, on in-traocular pressure in humans. Graefe's Arch. Ophthal-mol. (1991) 329:411.
- TH1ERAUCH K-H, STRZEBECHER C-ST, SCHILLINGER E, REHWINKEL H, RADCHEL B, SKUBALLA W, VORRBRGGEN H: Stable 93- or 1 la-halogen-15-cyclohenyl - pro-stag,landins with high affinity to the PGD2-receptor. Prostaglandins (1988) 35:855.
- WOODWARD DF, CHAN MF, CHENG-BENNE1T A et al.: In vivo activity and enzymatic hydrolysis of novel pro-staglandin F2a procirugs in ocular tissues Exp. Eye Res. (1996). In press.
- SUGIYAMA K, HAQUE SR, OKADA K et al.: The effect of an endothelin receptor antagonist, 97-139, on intraocu-lar pressure in rabbits. Nippon Ganka Gakkai Zassbri (1995) 99:271.
- HAQUE MSR, TANAGUCHI T, SUGIYAMA K, OKADA K,KITAZAWA Y: The ocular hypotensive effect of the ETB receptor selective agonist, safratoxin S6c, in rabbits. Invest. Ophthalmol. Vis. Sci. (1995) 36:804.
References to Patent Literature
- PHARMACOPAEIA, INC., W09524186 (1995).
- ALCON LABS., INC., WO 9519981 (1995).
- PROCTER AND GAMBLE CO., W09516449 (1995).
- PROCTER AND GAMBLE CO., W09516683 (1995).
- PROCTER AND GAMBLE CO., W09516685 (1995).
- PROCTER AND GAMBLE CO., W09520386 (1995).
- ALLERGAN, INC., W09519968 (1995).
- KABI PHARMACIA AB, US5296504 (1994).
- KABI PHARMACIA AB, US5321128 (1994).
- KABI PHARMACIA AB, US5422368 (1995).
- KABI PHARMACIA AB, US5422369 (1995).
- PHARMACIA AB, W09526729 (1995).
- PHARMACIA AB, W09525520 (1995).
- ALCON LABORATORIES, INC., EP-667160 (1994).
- TAISHO PHARMACEUTICAL CO. LTD., W09518101 (1995).
- ALCON LABORATORIES, INC., EP-639563 (1994).
- ALLERGAN, INC., US5352708 (1994).
- ALLERGAN, INC., US4994274 (1991)
- ALLERGAN, INC., US5028624 (1991).
- ALLERGAN, INC., US5446041 (1995).
- ALLERGAN, INC., US5288754 (1994).
- ALLERGAN, INC., US5476872 (1995).
- ALLERGAN, INC., US5416106 (1995).